Nexcella, Inc
Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, specializing in the development of cell therapies for AL amyloidosis and select immune-mediated diseases. As a subsidiary of Immix Biopharma, Nexcella is focused on pioneering CART therapy to improve patient outcomes and expand accessibility to transformative one-time treatments.
The company is currently conducting the NEXICART2 clinical trial, which evaluates the safety and efficacy of its investigational CART cell therapy, NXC201, for patients with relapsed and refractory AL amyloidosis. Nexcella aims to address the challenges of neurotoxicity associated with these treatments, making them available to a broader range of patients and medical centers across the United States.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.